Cell & Gene: The Podcast

EXPLORE

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/8a/93/ae/8a93aee4-2dc4-5598-abed-4634d1082726/mza_12322120778020472927.jpg/600x600bb.jpg

Cell & Gene: The Podcast

Erin Harris

99 episodes

15 hours ago

We love to hear from our listeners. Send us a message. In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases. Dr. Parmar shares the vision behind Cellenkos, the advantages of cord blood-derived Tregs over other sources, and how their CRANE technology platform enhances precision in targeting diseases. They als...

Show more...

All content for Cell & Gene: The Podcast is the property of Erin Harris and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

We love to hear from our listeners. Send us a message. In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases. Dr. Parmar shares the vision behind Cellenkos, the advantages of cord blood-derived Tregs over other sources, and how their CRANE technology platform enhances precision in targeting diseases. They als...

Show more...

Episodes (20/99)

Cell & Gene: The Podcast

CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D.

We love to hear from our listeners. Send us a message. Omkar Kawalekar, Ph.D., Senior Manager, NextGen Therapies Manufacturing & Supply Chain Lead, Deloitte Consulting joins Host Erin Harris to share his expert take on how distributed manufacturing models address capacity constraints and supply chain risks, the role of automation in reducing batch-to-batch variability, as well as the power of digital technologies in optimizing production processes. He also covers the key considerations fo...

2 weeks ago

28 minutes

Cell & Gene: The Podcast

Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali

We love to hear from our listeners. Send us a message. In this episode, Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insights on Tenaya's gene therapy platform, their in-house manufacturing capabilities, and the potential impact of their therapies on prevalent heart conditions. They also discuss the complexities of com...

4 weeks ago

35 minutes

Cell & Gene: The Podcast

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

We love to hear from our listeners. Send us a message.Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission for PRGN-2012, which includes Phase 1/2 pivotal study results where over 50% of patients achieved Comple...

1 month ago

26 minutes

Cell & Gene: The Podcast

The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

We love to hear from our listeners. Send us a message.Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling s...

1 month ago

24 minutes

Cell & Gene: The Podcast

Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.

We love to hear from our listeners. Send us a message.Cell & Gene: The Podcast Host Erin Harris talks to Christopher Choi, Ph.D., MBA, SVP Industry Partnership, Director of GMP and Cell Manufacturing Facility, and Associate Professor of Oncology at Roswell Park Comprehensive Cancer Center about the Center's Buffalo, NY-based cell and gene therapy hub slated to open in early 2025. They cover the increasingly important role of automation and digital technologies in CGT manufacturing. Choi a...

2 months ago

14 minutes

Cell & Gene: The Podcast

Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig

We love to hear from our listeners. Send us a message.Cell & Gene: The Podcast Host Erin Harris talks to Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) about the biggest challenges in developing gene therapies for cardiovascular diseases, specifically congestive heart failure (CHF). They discuss AB-1002, the gene therapy the company is developing for the treatment of CHF and why a gene therapy approach is sig...

2 months ago

21 minutes

Cell & Gene: The Podcast

Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rhakit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments. They cover the limitations of current PD medications, how cell therapies might offer a different approach to long-term symptom management, and how BlueRoc...

3 months ago

31 minutes

Cell & Gene: The Podcast

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

We love to hear from our listeners. Send us a message.Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on site during 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, an update on ARM's Grow Internship Program, as well as a few key takea...

3 months ago

21 minutes

Cell & Gene: The Podcast

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking a significant milestone as the first engineered T-cell therapy for solid tumors. Williams delves i...

4 months ago

20 minutes

Cell & Gene: The Podcast

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

We love to hear from our listeners. Send us a message.This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflammatory diseases shows great promise. They also cover this year's conference and what to expect during and after th...

4 months ago

25 minutes

Cell & Gene: The Podcast

Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

We love to hear from our listeners. Send us a message.Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoantigens as well as the potential benefits of TCR-T therapies for cancer treatment. Linnemann shares his thoughts on t...

5 months ago

14 minutes

Cell & Gene: The Podcast

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

We love to hear from our listeners. Send us a message.Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa.Subscribe to the podcast!Apple | Spotify | YouTube

5 months ago

22 minutes

Cell & Gene: The Podcast

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

We love to hear from our listeners. Send us a message.Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.Subscribe to the podcast!Apple | Spotify | YouTube

6 months ago

28 minutes

Cell & Gene: The Podcast

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

We love to hear from our listeners. Send us a message.Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is not one that is often cured. In this episode, Host Erin Harris follows up Roberts' article with in-dept...

6 months ago

25 minutes

Cell & Gene: The Podcast

CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

We love to hear from our listeners. Send us a message.Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also provides a regulatory outlook for CGT developers.Subscribe to the podcast!Apple | Spotify | YouTube

7 months ago

27 minutes

Cell & Gene: The Podcast

Identifying Drug Development Opportunities for DMD with CureDuchenne

We love to hear from our listeners. Send us a message.Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). Miller and Kelly also share their advice and recommendations for companies developing drugs for DMD...

7 months ago

29 minutes

Cell & Gene: The Podcast

Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington

We love to hear from our listeners. Send us a message.Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss why in vivo delivery continues to be a bottleneck against the clinical advancement of gene-editing-based medicines and what ultracompact CRISPR sys...

7 months ago

21 minutes

Cell & Gene: The Podcast

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

We love to hear from our listeners. Send us a message.KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune di...

8 months ago

35 minutes

Cell & Gene: The Podcast

Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft

We love to hear from our listeners. Send us a message.Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and intensity of expression of therapeutic proteins within the patient’s body, enabling precise and controlled delivery. They also cover the role synthet...

8 months ago

27 minutes

Cell & Gene: The Podcast

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko

We love to hear from our listeners. Send us a message.Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.Subscribe to the podcast!Apple | Spotify | YouTube

9 months ago

14 minutes